High cumulative doxorubicin dose for advanced soft tissue sarcoma
نویسندگان
چکیده
منابع مشابه
Systemic Treatment for Advanced Soft Tissue Sarcoma beyond Doxorubicin and Ifosfamide
Systemic therapy is the backbone in the management of advanced soft-tissue sarcoma.At present, anthracycline-based regimes represents the standard first-line treatment, but there are other active drugs widely used, providing additional therapeutic options and increasing overall survival among patients with advanced disease. Histologic subtype, patient characteristics, and expected toxicity prof...
متن کاملSequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule
Aims. This phase II study explored activity/safety of front-line dose-dense chemotherapy in high-grade STS (soft tissue sarcoma) patients and tested ezrin as prognostic factor. Patients and Methods. The protocol consisted of three cycles of doxorubicin (DOXO) 30 mg/m(2) on days 1-3 every 2 weeks, followed by three cycles of ifosfamide (IFO) 2.5 g/m(2) two hours a day on days 1-5 every 3 weeks, ...
متن کاملManagement of Advanced Adult Soft Tissue Sarcoma
The rare incidence and heterogeneous nature of soft tissue sarcomas (STS) are formidable barriers to the conduct of large randomised controlled trials (RCTs). A search of computer databases, using a Cochrane optimal search strategy 1966–1996, yielded less than 100 RCTs investigating the management of bone and soft tissue sarcomas (Bramwell 1997, Proceedings 5th Annual Cochrane Colloquium – unpu...
متن کاملDoxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Hyperthermic antiblastic perfusion/HAP) has been proven to be an effective neoadjuvant treatment in the treatment of advanced soft tissue limb sarcoma. As a matter of fact high percentage of limb sparing surgery, local control and functional results have been obtained wide this technique. Many antineoplastic drugs have been associated to hyperthermia by isolation limb perfusion, the aim of this...
متن کاملTargeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Soft tissue sarcomas comprise approximately 1% of all adult solid malignancies. While chemotherapy is the mainstay of treatment for patients with metastatic or inoperable disease, overall survival for these patients is approximately 12 months, highlighting the need for novel agents. Both laboratory and clinical data have suggested that antiangiogenic agents may have a role in the treatment of s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Cancer
سال: 2020
ISSN: 1471-2407
DOI: 10.1186/s12885-020-07663-x